Completed
Topics
Enacted in 2004, the EUA authority allows FDA to sanction on an expedited basis the sale of unapproved medical products for use in public health emergencies. The EUA has become critically important during the COVID-19 pandemic. Nevertheless, the criteria for issuing an EUA are not well-defined in the statute or in FDA regulations. This workshop examined the FDA's historic and recent use of the EUA. We explored possible additional regulatory standards or guidance that could help ensure that EUAs are based on the best scientific evidence and build public confidence the EUA process and products.